Technology

Artelus wins Roche Drishti HealthTech Challenge

Published

4 months ago

June 26, 2026

Drishti HealthTech Challenge is a joint initiative by DPIIT and Roche Pharma India under the Startup India program80+ startups submitted their applicationsArtelus will receive a financial grant of INR 35 lakhs to co-develop and pilot its winning solution

NEW DELHI, June 26, 2026 /PRNewswire/ — Leading healthcare startup ‘Artelus’ – an AI-based provider of healthtech solutions, aiming to enhance diagnosis and treatment for improved patient outcomes was recognised as the winner of Startup India’s Drishti HealthTech Challenge, a joint initiative by the Department for Promotion of Industry and Internal Trade (DPIIT) and Roche Pharma India. This recognition is a testimony to the rapid progress made by homegrown health tech startups who are disrupting India’s healthcare landscape.

Aimed at identifying and supporting healthtech startups in India to develop transformative, scalable solutions for some of the country’s most important health challenges, the Drishti HealthTech Challenge received high-impact applications from 80+ startups working in the areas of digital health.

The Jury comprising of retinal health experts, startup mentors and select members of the Roche India leadership evaluated the applications through a rigorous, multi-stage evaluation criteria focused on problem relevance, impact potential, market readiness, leadership credibility, and regulatory, legal & IP moats. Artelus emerged as the winner and will receive a financial grant of INR 35 lakhs to co-develop, enhance and pilot its pioneering solution in partnership with Roche Pharma India.

The award ceremony, hosted at the Swiss Embassy in New Delhi in the presence of Her Excellency, Mrs. Maya Tissafi, Ambassador of Switzerland to India and Bhutan, marks another milestone in Indo-Swiss collaboration, driven by Roche’s partnership with Startup India and DPIIT to strengthen the healthcare ecosystem in India.

Her Excellency, Mrs. Maya Tissafi, Ambassador of Switzerland to India and Bhutan, said, “The Trade and Economic Partnership Agreement between EFTA and India has intensified the economic relationship between our countries. It creates a ground for exactly the kind of innovation we see today – such as this initiative by Roche Pharma India and Startup India, which creates platforms for entrepreneurs and supports opportunities for collaboration and brings us closer to real-world impact. I would like to offer special congratulations to the winning start-up, Artelus. Its work shows how healthtech can make early diagnosis more accessible and bring quality healthcare closer to those who need it.”

Shri Ateesh Kumar Singh, Additional Secretary, DPIIT, said, “Fostering an ecosystem where advanced technology seamlessly integrates with grassroots healthcare delivery is key to sustainable economic development. Initiatives like the Roche Drishti HealthTech Challenge underscore the immense potential of the Indian startup community to deliver high-impact solutions. Startup India, DPIIT remains committed to supporting open innovation frameworks that empower homegrown entrepreneurs to scale their impact across the country.”

Roche Pharma India Managing Director & CEO Rajji Mehdwan, said, “Retinal diseases are stealing sight across India. The healthcare community has clinicians dedicated to helping people and the medicines that can truly make a difference. What we didn’t have was a way to make early diagnosis accessible to everyone. Artelus solves that. Their offline AI technology brings screening to places we’ve never been able to reach before—expanding access to a much wider group of people. That changes everything. No patient should lose their vision to something preventable. Our partnership with DPIIT and Startup India reflects Roche’s unyielding commitment to India’s innovation ecosystem, nurturing local, home-grown solutions for India’s unique healthcare challenges.”

About the winning solution

Diabetic Retinopathy (DR) is a rapidly growing public health crisis in India, with delayed diagnosis leading to preventable blindness. The Drishti HealthTech Challenge was launched to uncover scalable, tech-enabled solutions to address this gap.

Artelus’s winning innovation—DRISTi (Diabetic Retinopathy Screening)—is an instantaneous, CE Class 1 AI product that completely redefines point-of-care diagnostics. By building a one-of-its-kind ‘AI on a Chip,’ Artelus enables fully offline retinal screening that functions entirely without internet or cloud connectivity. Alongside their backpack-friendly, 5G-enabled OCT systems, this breakthrough tech democratizes healthcare by bringing comprehensive, transparent retinal diagnostics directly to the remotest corners of India.

Girish Somvanshi, Co-Founder & VP, Artelus, said, “Breakthrough therapies save vision only when patients access treatment in a timely manner. The Roche Drishti Healthtech Challenge recognizes the critical importance of closing that gap. At Artelus, we are building the infrastructure to ensure every patient is identified, referred, treated, and followed up – at a population scale optimized for India and the rest of the world.”

About the Roche Drishti HealthTech Challenge

The Drishti HealthTech Challenge, launched on the Startup India platform is a joint initiative by DPIIT and Roche aimed at strengthening India’s innovation ecosystem and advancing transformative solutions in healthcare. It invited applications from startups working in the following areas of retinal health:

AI driven early screening, referral, and treatment pathways for retinal diseasesA unified, interoperable RWE platform that can integrate with existing systems

About Artelus

Artelus is an award-winning Indian healthtech company building innovative AI-powered portable diagnostics, and digital health infrastructure to enable early detection and integrated management of retinal diseases. With a mission to make quality eye care accessible, affordable, and available to populations worldwide, its solutions are deployed across hospitals, public health programs, NGOs, and international markets, helping reduce avoidable blindness at scale.

About Roche Products (India) Pvt. Ltd.

Roche Products (India) Private Limited is as a wholly owned subsidiary of the Roche Group, the world’s largest biotech company headquartered in Basel, Switzerland. For 80+ years, Roche has been dedicated to improving lives in India, evolving from Vitamins in the 1940s to advanced, differentiated medicines for cancer, ophthalmology, neurology and blood disorders. For more information, visit www.rocheindia.com

Photo: https://mma.prnewswire.com/media/3001060/Roche_DHTC.jpg
Logo: https://mma.prnewswire.com/media/2937896/5873139/Roche_Logo.jpg

View original content to download multimedia:https://www.prnewswire.com/in/news-releases/artelus-wins-roche-drishti-healthtech-challenge-302811738.html

Technology

MiniTool ShadowMaker 5.0 Introduces Cloud Sync for Google Drive and OneDrive

Published

33 minutes ago

October 23, 2026

VANCOUVER, BC, Oct. 22, 2026 /PRNewswire/ — MiniTool® Software Limited has announced the release of MiniTool ShadowMaker 5.0, the latest version of its Windows backup and file sync software. The update introduces a new Cloud Sync feature for Google Drive and OneDrive, along with enhancements to the registration and purchase experience, interface refinements, and compatibility fixes.

New Features and Improvements in MiniTool ShadowMaker 5.0

1. Cloud Sync to Google Drive and OneDrive

MiniTool ShadowMaker 5.0 introduces Cloud Sync, allowing users to synchronize files and folders from a Windows computer to Google Drive or OneDrive. Users can choose the files and folders they want to sync and select their preferred cloud storage service as the destination.

The new feature supports one-way synchronization from a local Windows PC to cloud storage, providing an additional way to save copies of important files outside of your computer. Together with MiniTool ShadowMaker’s existing local file sync function, Cloud Sync expands the available destinations for file sync.

2. Streamlined License & Plan Management

The latest update introduces an enhanced register interface that remains easily accessible even after activation. Registered users can now effortlessly review their current plan, explore upgrade options, or update their license key anytime for a smoother user experience.

These refinements are intended to improve usability when users manage their software registration and licensing.

3. Interface Refinements and Compatibility Fixes

MiniTool ShadowMaker 5.0 includes interface improvements and fixes for certain display issues. One notable fix addresses a blurry display issue that could occur on some systems equipped with AMD GPUs.

These changes focus on resolving specific issues and improving the user experience on affected systems.

4. Additional Improvements

Beyond Cloud Sync and the changes outlined above, MiniTool ShadowMaker 5.0 includes additional interface and functionality refinements. Together, these updates further improve the software’s usability while expanding its file synchronization options.

With support for Google Drive and OneDrive, MiniTool ShadowMaker 5.0 provides Windows users with another approach to manage file copies across local and cloud storage. Users who want to synchronize files to cloud storage can download the Free Edition and explore the new capabilities.

About MiniTool ShadowMaker

MiniTool ShadowMaker is a Windows backup and file sync solution designed to help users protect their operating systems and important data. It supports backing up Windows systems, disks, partitions, files, and folders to local drives, external hard drives, shared folders, and other supported locations. Users can select specific items to back up according to their needs.

For users who need to migrate data to another drive, MiniTool ShadowMaker offers a disk cloning feature. The software also supports restoring backed-up data and creating bootable media for system recovery.

By combining backup, file synchronization, disk cloning, and restore capabilities, MiniTool ShadowMaker offers Windows users a set of tools for data protection and system recovery.

About MiniTool® Software Limited

MiniTool Software Limited is a professional software company that develops computer applications. It provides software for partition management, data recovery, data backup and sync, video editing, multimedia conversion, and screen recording for home and business users. The company is committed to developing innovative, reliable, and easy-to-use software that simplifies everyday digital tasks.

View original content to download multimedia:https://www.prnewswire.com/news-releases/minitool-shadowmaker-5-0-introduces-cloud-sync-for-google-drive-and-onedrive-302916663.html

SOURCE MiniTool® Software Limited

Technology

Rocket Companies to Announce Third Quarter 2026 Results on October 29, 2026

Published

2 hours ago

October 22, 2026

DETROIT, Oct. 22, 2026 /PRNewswire/ — Rocket Companies, Inc. (NYSE: RKT) (“Rocket Companies” or “the Company”), the Detroit-based homeownership platform, today announced that the Company will issue its third quarter 2026 earnings on October 29, 2026. Leadership will host a conference call to discuss results at 4:30 p.m. ET on that date. A press release detailing the Company’s results will be issued prior to the call.

A live webcast of the event will be available on the “Events & Presentations” section of the Company’s Investor Relations website at ir.rocketcompanies.com. A replay of the webcast will be available on the Investor Relations website following the event.

About Rocket Companies

Founded in 1985, Rocket Companies (NYSE: RKT) is a Detroit-based homeownership platform including mortgage, real estate and personal finance businesses: Rocket Mortgage, Redfin, Rocket Close, Rocket Money and Rocket Loans.

With insights from more than 160 million calls with clients each year, more than 30 petabytes of data and a mission to Help Everyone Home, Rocket Companies is well positioned to be the destination for AI-fueled homeownership.

For more information, please visit the Company’s Corporate website or Investor Relations website.

View original content to download multimedia:https://www.prnewswire.com/news-releases/rocket-companies-to-announce-third-quarter-2026-results-on-october-29-2026-302917496.html

SOURCE Rocket Companies, Inc.

Technology

Lunai Bioworks Announces Receipt of Nasdaq Determination and Intention to Voluntarily Delist and Deregister

Published

2 hours ago

October 22, 2026

SACRAMENTO, Calif., Oct. 22, 2026 /PRNewswire/ — Lunai Bioworks Inc. (Nasdaq: LNAI) (the “Company”) announced that on October 21, 2026, it received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) stating that the Company no longer complies with Nasdaq Listing Rule 5550(b)(1), which requires minimum stockholders’ equity of $2,500,000. The Company reported a stockholders’ deficit of $(9,024,946) in its Annual Report on Form 10-K for the fiscal year ended June 30, 2026, and does not meet the alternative market value of listed securities or net income standards. Because the Company is subject to a mandatory Hearings Panel Monitor under Nasdaq Listing Rule 5815(d)(4)(B), Nasdaq staff determined to delist the Company’s securities. Trading in the Company’s common stock on Nasdaq is expected to be suspended at the opening of business on October 30, 2026.

The Company will not request a hearing. Rather than contest the staff determination, the Company’s Board of Directors approved on October 22, 2026 the voluntary withdrawal of the Company’s common stock from listing on Nasdaq under Rule 12d2-2(c) under the Securities Exchange Act of 1934, as amended. The Board took this action because of the staff determination and the Company’s financial condition, and concluded that the cost of continued listing and SEC reporting is not justified.

The Company notified Nasdaq of its intention on October 22, 2026. The Company intends to file a Form 25 with the Securities and Exchange Commission (the “SEC”) on or about November 2, 2026, and expects the delisting to become effective on or about November 12, 2026. The Company then intends to file a Form 15 to suspend its SEC reporting obligations, to the extent it is eligible to do so. The Company’s SEC reporting obligations will continue unless and until they are terminated or suspended in accordance with the SEC’s rules.

The Company does not intend to arrange for quotation of its common stock on any over-the-counter market and cannot assure that any trading market for its common stock will exist after trading on Nasdaq is suspended.

Forward-Looking Statements
This press release contains forward-looking statements, including statements regarding the expected suspension of trading, the expected timing of the Form 25 and Form 15 filings, and the expected timing of delisting and deregistration. Actual results may differ materially due to risks and uncertainties, including Nasdaq and SEC procedures and the Company’s financial condition. The Company undertakes no obligation to update these statements, except as required by law.

View original content to download multimedia:https://www.prnewswire.com/news-releases/lunai-bioworks-announces-receipt-of-nasdaq-determination-and-intention-to-voluntarily-delist-and-deregister-302917510.html

SOURCE Lunai Bioworks Inc.